Who Supplies Famotidine to India from UNITED STATES

Importing finished pharmaceutical formulations containing Famotidine into India requires compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations. Importers must obtain a valid Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with CDSCO, which involves submitting Form CT-20/40/41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and stability data. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory workload. For Famotidine formulations under HS Code 30049039, specific requirements include demonstrating compliance with the Indian Pharmacopoeia standards and providing evidence of safety and efficacy.

Imported Famotidine formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure product integrity in India's climate. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. Failure to meet these requirements can result in delays, rejections, or destruction of the goods.

Between 2024 and 2026, the Indian government has implemented several regulatory updates affecting pharmaceutical imports. The Production-Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements with the United States have been strengthened, facilitating smoother trade and mutual recognition of Good Manufacturing Practices (GMP). These changes aim to balance the promotion of domestic industry with the need for high-quality imported pharmaceuticals.

India imports finished Famotidine formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as injectables or extended-release tablets, may not be produced locally. Despite a robust domestic pharmaceutical industry, certain formulations are imported to fulfill market needs. The market size for Famotidine formulations in India is substantial, with imports contributing significantly to the total consumption.

The import duty structure for Famotidine formulations under HS Code 30049039 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10% on the BCD, and an Integrated Goods and Services Tax (IGST) of 12%. This results in a total landed duty of approximately 32.2% on the CIF (Cost, Insurance, and Freight) value. Exemptions may apply under specific trade agreements or for certain product categories.

India sources Famotidine formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. While other suppliers like China and Germany also export Famotidine formulations to India, the United States maintains a competitive advantage in terms of product innovation and regulatory compliance. The U.S. share in India's Famotidine import market is significant, reflecting strong trade relations and mutual trust in pharmaceutical quality.

India imports Famotidine formulations from the United States due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Certain formulations, such as extended-release tablets or specific combinations, may not be produced domestically, necessitating imports to meet market demand.

Compared to other origins like China and Germany, the United States offers a competitive advantage in terms of product innovation, quality assurance, and regulatory compliance. U.S. manufacturers adhere to stringent Good Manufacturing Practices (GMP), ensuring high-quality products that meet international standards. This commitment to quality makes U.S. Famotidine formulations a preferred choice for Indian importers.

Indian importers face several supply chain risks when sourcing Famotidine formulations from the United States, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have occurred due to manufacturing issues or logistical challenges. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, and maintain robust quality assurance processes.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain adequate inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory management.
5. 5Supplier Qualification: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities and reviews of quality certifications, to ensure compliance with regulatory standards.

1. 1DGFT Import License: Obtain a valid Drug Import License from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation, including submission of Form CT-20/40/41.
3. 3Drug Import License: Ensure the license covers the specific product and complies with Indian regulations.
4. 4No Objection Certificate (NOC): If required, obtain an NOC from the manufacturer or relevant authority.
5. 5Customs Broker: Engage a licensed customs broker to facilitate the import process.
6. 6Advance Ruling: Seek an advance ruling from customs on classification and duty rates for HS Code 30049039.

SECTION: